Caron Justin E, March Jordon K, Cohen Michael B, Schmidt Robert L
Department of Pathology and ARUP Laboratories, University of Utah Health Sciences Center, Salt Lake City.
Am J Clin Pathol. 2017 Oct 1;148(4):314-322. doi: 10.1093/ajcp/aqx080.
To determine the prevalence of reporting guideline endorsement in pathology journals and to estimate the impact of guideline endorsement.
We compared the quality of reporting in two sets of studies: (1) studies published in journals that explicitly mentioned a guideline vs studies published in journals that did not and (2) studies that cited a guideline vs studies that did not. The quality of reporting in prognostic biomarker studies was assessed using the REporting recommendations for tumor MARKer prognostic studies (REMARK) guideline.
We found that six (10%) of the 59 leading pathology journals explicitly mention reporting guidelines in the instructions to authors. Only one journal required authors to submit a checklist. There was significant variation in the rate at which various REMARK items were reported (P < .001). Journal endorsement was associated with more complete reporting (P = .04). Studies that cited REMARK had greater adherence to the REMARK reporting guidelines than studies that did not (P = .02).
The prevalence of guideline endorsement is relatively low in pathology journals, but guideline endorsement may improve the quality of reporting.
确定病理学杂志中报告指南认可的流行程度,并评估指南认可的影响。
我们比较了两组研究中的报告质量:(1)在明确提及指南的杂志上发表的研究与在未提及指南的杂志上发表的研究,以及(2)引用指南的研究与未引用指南的研究。使用肿瘤标志物预后研究报告建议(REMARK)指南评估预后生物标志物研究中的报告质量。
我们发现,59种主要病理学杂志中有6种(10%)在作者须知中明确提及报告指南。只有一本杂志要求作者提交清单。不同REMARK项目的报告率存在显著差异(P <.001)。杂志认可与更完整的报告相关(P =.04)。引用REMARK的研究比未引用的研究更严格遵守REMARK报告指南(P =.02)。
病理学杂志中指南认可的流行程度相对较低,但指南认可可能会提高报告质量。